Though guidelines suggest screening starts at 50, researcher says it's premature to change them
by Tham on Mon Apr 20, 2009 12:00 AM
NSCLC - Cetuximab (Erbitux) with Erlotinib (Tarceva), other drugs or radiation. The first looks the most promising.Recruiting :http://clinicaltrials.gov/ct2/show/NCT00408499 http://clinicaltrials.gov/ct2/show/NCT00842712 http://clinicaltrials.gov/ct2/show/NCT00673738 http://clinicaltrials.gov/ct2/show/NCT00343291 http://clinicaltrials.gov/ct2/show/NCT00492206 Recruiting later.http://clinicaltrials.gov/ct2/show/NCT00820755
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
We care about your feedback. Let us know how we can improve your CancerCompass experience.